CMMB Insider Trading

Insider Ownership Percentage: 11.91%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Chemomab Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Chemomab Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chemomab Therapeutics Share Price & Price History

Current Price: $0.99
Price Change: Price Increase of +0.0551 (5.92%)
As of 06/24/2024 03:28 PM ET

This chart shows the closing price history over time for CMMB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Chemomab Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2023Israel Gp Ltd. OrbimedMajor ShareholderSell336,900$3.58$1,206,102.002,241,274View SEC Filing Icon  
11/16/2022George Adi MorInsiderSell324,775$2.08$675,532.00324,775View SEC Filing Icon  
11/16/2022Neil Harris CohenDirectorSell2,409$2.00$4,818.0010,000View SEC Filing Icon  
3/18/2022Joel Michael MarylesDirectorBuy1,000$4.34$4,340.00View SEC Filing Icon  
3/16/2022Donald MarvinCFOBuy500$3.27$1,635.002,000View SEC Filing Icon  
3/14/2022Dale R PfostCEOBuy2,500$3.98$9,950.00View SEC Filing Icon  
3/14/2022Donald MarvinCFOBuy1,250$4.04$5,050.00View SEC Filing Icon  
3/14/2022Neil Harris CohenDirectorBuy6,000$4.35$26,100.00View SEC Filing Icon  
12/6/2021Neil Harris CohenDirectorBuy2,000$7.43$14,860.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Chemomab Therapeutics (NASDAQ:CMMB)

46.05% of Chemomab Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CMMB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Chemomab Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/1/2023Kestra Private Wealth Services LLC31,241$100K0.0%N/A0.271%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP11,277$78K0.0%N/A0.099%Search for SEC Filing on Google Icon
1/28/2022ARK Investment Management LLC267,292$1.84M0.0%+48.1%2.344%Search for SEC Filing on Google Icon
11/17/2021Yahav Achim Ve Achayot Provident Funds Management Co Ltd.3,097$34K0.0%N/A0.027%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.54,821$0.61M0.0%N/A0.481%Search for SEC Filing on Google Icon
11/3/2021Meitav Dash Investments Ltd.37,567$0.42M0.0%-7.6%0.330%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC13,180$0.25M0.0%N/A0.116%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace LLP63,554$1.21M0.0%N/A0.558%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace North America L.P.44,035$0.84M0.0%N/A0.386%Search for SEC Filing on Google Icon
8/18/2021Ikarian Capital LLC290,534$5.53M0.4%N/A2.640%Search for SEC Filing on Google Icon
8/18/2021Meitav Dash Investments Ltd.40,664$0.77M0.0%+389.3%0.370%Search for SEC Filing on Google Icon
8/17/2021Boothbay Fund Management LLC54,729$1.04M0.0%-11.4%0.512%Search for SEC Filing on Google Icon
8/16/2021Marshall Wace LLP63,554$1.21M0.0%N/A0.594%Search for SEC Filing on Google Icon
8/5/2021Meitav Dash Investments Ltd.40,664$0.77M0.0%+389.3%0.380%Search for SEC Filing on Google Icon
5/18/2021Orbimed Advisors LLC2,578,174$74.02M0.7%N/A110.320%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC7,023$0.20M0.0%N/A0.301%Search for SEC Filing on Google Icon
5/6/2021Meitav Dash Investments Ltd.8,311$0.24M0.0%N/A0.356%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Chemomab Therapeutics logo
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Read More on Chemomab Therapeutics

Today's Range

Now: $0.99
Low: $0.92
High: $0.99

50 Day Range

MA: $0.87
Low: $0.59
High: $1.29

52 Week Range

Now: $0.99
Low: $0.42
High: $1.50

Volume

53,098 shs

Average Volume

172,251 shs

Market Capitalization

$10.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Who are the company insiders with the largest holdings of Chemomab Therapeutics?

Chemomab Therapeutics' top insider investors include:
  1. Israel Gp Ltd Orbimed (Major Shareholder)
  2. George Adi Mor (Insider)
  3. Neil Harris Cohen (Director)
Learn More about top insider investors at Chemomab Therapeutics.